Supplementary Figures from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Authors:
  • PHPaul E. Hughes
    Paul E. Hughes
  • KRKaren Rex
    Karen Rex
  • SCSean Caenepeel
    Sean Caenepeel
  • YYYajing Yang
    Yajing Yang
  • YZYihong Zhang
    Yihong Zhang
  • MBMartin A. Broome
    Martin A. Broome
  • HKHue T. Kha
    Hue T. Kha
  • TBTeresa L. Burgess
    Teresa L. Burgess
  • BABenny Amore
    Benny Amore
  • PKPaula J. Kaplan-Lefko
    Paula J. Kaplan-Lefko
  • JMJodi Moriguchi
    Jodi Moriguchi
  • JWJonathan Werner
    Jonathan Werner

Abstract
Figure S1. Kinase interaction map for AMG 337; Figure S2. In a large unbiased cancer cell line viability screen only MET-amplified cell lines were sensitive to treatment with an analogue of AMG 337 (Compound 5); Figure S3: AMG 337 inhibits the phosphorylation of MET and but not its downstream effectors in MET-amplified, KRAS mutant NSCLC cell line NCI-H1573; Figure S4. Cell lines harboring MET FISH scores >3 exhibited sensitivity to AMG 337. MET FISH analysis was performed on a subset of cancer cell lines exhibiting elevated MET gene copy number; Figure S5. Selective inhibition of MET exhibits partial effects on the viability of U-87 MG glioblastoma cells harboring an HGF/MET autocrine loop; Figure S6. Increases in MET gene number correlate with high levels of total MET protein; Figure S7. AMG 337 inhibits Gab-1 phosphorylation in a concentration dependent manner in the TPR-MET mouse tumor model.